Larkin JMG, et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma. Abstract LBA68_PR. ESMO Congress 2019, 28 sept, Barcelona, Spanje.
Hoge dosis chemotherapie niet beter dan chemoradiotherapie bij ewingsarcoom met longmetastasen
dec 2019 | Longoncologie, Radiotherapie